查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836847

醫藥契約製造市場按服務類型、分子類型、劑型、客戶類型、治療領域、合約類型、製造規模和製程類型分類 - 全球預測，2025-2032 年

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥契約製造市場規模將成長至 2,411.6 億美元，複合年成長率為 8.70%。

主要市場統計數據
基準年2024年 1236.4億美元
預計2025年 1344.4億美元
預測年份：2032年 2411.6億美元
複合年成長率（%） 8.70%

關於契約製造如何從成本主導的選擇轉變為醫藥創新和供應彈性的戰略能力的權威定位

醫藥受託製造領域在全球醫藥供應鏈中發揮著至關重要的作用，使創新者、學名藥製造商和生物相似藥開發商能夠將實驗室突破轉化為可擴展且受監管的商業產品。外包製造、配方開發、分析測試和包裝已從一種成本控制策略發展成為一種戰略能力，有助於加快產品上市速度、提高產品組合靈活性並分散風險。如今，價值鏈上的相關人員不再將受託製造廠商(CMO) 視為單純的產能供應商，而是將共用技術風險、合規管道和生命週期管理責任的合作夥伴。

當今的格局受到多重壓力的影響：複雜的生技藥品形式需要專業的無菌和低溫運輸能力；監管部門對穩健的品質系統和供應可追溯性的期望；以及商業領域對更快的臨床到商業化轉型的需求。在這些動態中，整合開發專業知識、分析深度和商業規模生產的一體化服務模式正變得越來越重要。因此，具有前瞻性的申辦者優先考慮長期技術合作關係、模組化生產佈局和供應風險透明度，並將受託製造定位為其藥物創新和分銷策略的核心節點。

技術進步、監管加強和地緣政治壓力如何共同重新定義製造外包能力和戰略採購模式

在技​​術進步、監管日益複雜以及相關人員不斷變化的期望的推動下，近期趨勢正在迅速改變支持藥物開發和商業化的受託製造格局。先進生技藥品、細胞和基因療法的興起正推動合約製造生產組織 (CDMO) 投資無菌注射和低溫運輸平台，而持續生產和工藝集約化正在重新定義製造經濟學和設施設計。這些轉變並非孤立存在；它們同時再形成了整個產業的商業性採購模式、資本規劃和人才需求。

全球監管機構對設計品質、流程穩健性和供應鏈透明度的要求日益提高，這促使製造商及其合作夥伴在整個開發和製造生命週期中嵌入分析和數位線程功能。同時，該行業的地理佈局正在適應地緣政治和貿易趨勢，本地製造能力、雙重採購策略和近岸外包正在成為緩解干擾的機制。總而言之，這些變革力量有利於那些能夠展示平台標準化、跨模式專業知識以及將監管、技術和商業需求整合到一致交付模式中的敏捷方法的契約製造製造商。

了解 2025 年美國新關稅的廣泛營運和商業影響，以及它們將如何重塑採購、投資和承包策略

美國將於2025年生效的關稅措施調整，將給藥品成分、包裝組件、資本設備等採購計算帶來新的複雜性，迫使契約製造製造商及其贊助商客戶重新評估其成本結構和供應風險模型。某些進口材料和設備的關稅上調，推高了無菌填充、專用包裝基材、先進分析設備等關鍵零件的到岸成本。臨床供應預算面臨壓力，新設施和設備的資本支出計畫需要重新調整，贊助商和CDMO之間的定價談判必須考慮到不斷上升的投入成本波動。

除了直接的成本影響外，關稅還在加速改變長期產業結構的策略行動。一些發起人正在優先考慮重新共享和近似共享舉措，以減少貿易摩擦的影響，從而增加了對無菌藥品、生技藥品灌裝和特種包裝國內生產能力的需求。擁有靈活生產模式和多個地理位置的契約製造製造商正受到尋求快速緊急應變方案和更短物流鏈的客戶日益成長的興趣。同時，受關稅影響地區的原料供應商正在探索重新認證途徑、雙重採購安排和關稅工程解決方案，以保持競爭力。

這些政策變化的累積效應也反映在供應商談判和商業合約中。成本升級條款、轉嫁機制和庫存融資安排正成為新契約的重點。申辦者和CDMO正在尋求提高材料成分和來源的透明度，並越來越同意長期採購承諾以確保價格穩定。此外，監管機構和行業協會正在進行對話，以維持基本藥品的供應連續性，促使相關人員制定了應急方案，將戰略庫存、多個製造地和關鍵成分的優先分配框架結合起來。

簡言之，2025年的關稅並非暫時的價格衝擊，而是結構性變革的催化劑。關稅促使籌資策略轉向彈性和在地化，提升了製造彈性的價值，並迫使商業環境與供應鏈現實更加協調一致。積極將關稅風險納入情境規劃、資本投資決策和供應商管治的企業，將更有能力維持供應連續性，並保障淨利率，同時確保合規性和產品品質。

策略性細分分析揭示了服務、分子、劑型、客戶原型、治療重點細分、合約模式、製造規模和製程選項等方面的產能需求

細緻的細分視角揭示了服務模式、分子類別、劑型、客戶原型、治療重點、合約模式、製造階段和製程設計方案等方面的能力差距和策略重點。服務類型的專業化涵蓋：涵蓋生物分析操作、分析方法開發和穩定性測試的分析服務；涵蓋配方和製程開發的開發服務；包括注射器、單位劑量和管瓶灌裝的灌裝服務；面向液體口服劑型、固體口服劑型、無菌注射劑和外用劑型的製造服務；以及滿足一級和二級包裝需求的包裝和標籤服務。每種服務所需的資本強度、監管管道和技術能力各不相同，能夠提供開發、分析表徵和商業化生產之間整合交接的公司將為申辦者創造上市時間優勢。

分子類型決定了技術複雜性和設備要求。生技藥品需要專門的上游和下游製程、低溫運輸考量和無菌處理方案，而小分子通常適用於成熟的口服口服固體製劑和液體生產平台。液體製劑（包括口服溶液和混懸液）需要輔料採購和穩定性方面的專業知識；固態膠囊和片劑需要強大的配方開發和壓片灌裝能力；無菌注射劑需要嚴格的無菌操作和檢驗的灌裝設備；局部製劑（例如乳膏、軟膏和凝膠）需要配方流變性控制和容器相容性測試。

客戶類型和治療領域決定了商業性參與模式。生物相似藥製造商通常尋求大量商業化生產能力和法規可比性方面的專業知識，學名藥藥製造商優先考慮快速擴大規模和經濟高效的工具，而創新藥製造商則要求整合的開發管道和管理技術轉移。心血管、中樞神經系統、感染疾病和腫瘤等治療領域有不同的要求，包括臨床供應鏈時間安排、包裝和標籤的複雜性以及監管互動。產品類型和生產規模引入了管治和利用動態。專用合約提供保證的生產能力和長期協調，而非專用模式則提供了靈活性，但需要更複雜的調度。臨床規模生產對I、II和III期試驗有獨特的需求，需要快速的技術轉移和批次文件實踐，這與商業規模的營運有很大不同。最後，流程類型（批量或連續）會影響資本部署、流程監控的複雜性和擴大規模的影響。連續製程可以為某些模式實現更高的吞吐量和更穩定的產品質量，但需要更先進的製程控制和即時分析能力。將能力與這些細分軸進行映射，可以讓相關人員確定在哪裡加強夥伴關係、在哪裡投資能力發展以及在哪裡優先降低風險以支持治療和商業目標。

美洲、歐洲、中東和非洲以及亞太地區的製造能力、監管複雜性和策略獎勵如何影響製造足跡和採購決策

區域動態正在影響製造能力的建設地點、供應風險的管理方式以及哪些監管機構主導商業性考量。在美洲，對無菌注射劑、填充封口先進生技藥品以及安全供應鏈的需求正在推動國內製造能力的投資和專業化。該地區監管清晰、商業市場龐大且靠近主要申辦方總部，這些優勢使其對近岸外包計劃以及尋求更短前置作業時間和更快速技術合作的申辦方具有吸引力。

歐洲、中東和非洲的監管格局和能力各異，成熟的CDMO和利基創新企業並存。歐洲製造網路通常強調統一的監管途徑和先進的工藝技術，而該地區其他國家則提供差異化的成本結構和新興的專業能力。區域內跨境監管的一致性會影響多國的批次放行策略以及集中品質監控的實施地點，進而影響多站點製造網路的設計。

亞太地區繼續成為重要的製造能力中心，為小分子藥物、學名藥生技藥品和無菌製劑提供廣泛的製造地。該地區憑藉其成本競爭力、深厚的輔料和包裝材料供應商網路以及不斷壯大的技術人才庫，成為臨床和商業生產的中心。同時，亞太地區多個市場日益完善的法規和不斷成長的國內需求，正推動當地供應商升級品質系統並尋求國際認證。

在這些全部區域，供應鏈韌性、監管趨同以及對本地製造的策略獎勵是影響投資決策的通用主題。申辦方和製造外包製造商在配置其全球佈局時，必須權衡成本、前置作業時間、監管複雜性和風險敞口。

探索能力整合、平台專業化和深度客戶夥伴關係如何改變合約製造公司的競爭定位

領先的合約製造和服務供應商的競爭動態體現在能力整合、平台差異化以及超越交易關係的深化客戶夥伴關係關係。許多公司正在透過提供從開發到商業的一體化解決方案來提升價值鏈，以減少技術轉移中的摩擦並加快商業化進程。這一趨勢體現在擴展分析平台以支援複雜的生技藥品、投資無菌填充能力，以及採用數位化品質和製造執行系統以實現更可預測的結果。

策略夥伴關係、合併以及有針對性的待開發區投資正被用於擴大醫療模式覆蓋範圍和地理佈局，而中型專科參與企業往往透過專注於諸如高效價處理、複雜包裝或快速臨床供應等利基能力而取得成功。對於申辦者而言，合作夥伴的選擇反映了規模、技術專長和監管經驗深度之間的平衡。採購團隊越來越優先考慮那些能夠證明可驗證的流程穩健性、成功的技術轉移記錄以及對多供應商供應鏈進行透明管治的合作夥伴。

人才和領導的持續性是關鍵的差異化因素。擁有涵蓋研發科學、法規事務、品質保證和卓越營運等跨職能團隊的組織，更有能力推進複雜計劃，並最大程度地減少產品發布延遲。此外，提供清晰的產能擴張藍圖和緊急應變計畫的公司，往往能獲得尋求降低產品發布和生命週期供應風險的客戶所做出的長期承諾。

製造商和贊助商可以採取切實可行的策略行動，以提高靈活性、降低供應風險，並使商業性框架與不斷發展的製造業現實保持一致

產業領導者應優先考慮一系列戰術性和戰略行動，將當前的市場動態轉化為永續優勢。首先，選擇性地投資模組化、靈活的生產平台，這些平台可以容納多種劑型和分子類別，從而實現計劃之間的快速重新部署，並​​減少設備重組的時間。整合強大的分析技術和數位化流程控制，支持「品質源自於設計」的概念，並使從臨床到商業化生產的規模化進程更加順暢。

其次，重新評估您的供應商和籌資策略，以降低海關和物流風險。這可能包括多元化投入品供應商、協商更清晰的轉嫁條款，以及在可行的情況下開發近岸替代方案。透明的原產地證明文件和積極主動的供應商資格審查方法將提升您的談判能力，並減少下游意外情況。

第三，透過將製劑、分析和製程開發團隊與生產團隊並置或緊密整合，加強一體化開發管道。這種合作可以縮短反饋循環，加速技術轉移，並減少規模化生產過程中的監管摩擦。此外，還要製定正式的應急方案，以應對關鍵材料短缺或監管延遲，包括優先分配標準以及與值得信賴的合作夥伴預先商定的突波能安排。

第四，與客戶採用以結果為導向的商業模式，例如里程碑掛鉤定價和風險分擔安排，以更好地協調獎勵並應對投入成本波動。制定合約框架，其中包含明確的投入成本衝擊升級機制，同時維持變革管理的協作管治。最後，優先發展人才發展項目，對科學家、品質專業人員和營運人員進行交叉培訓，以增強組織韌性，並在關鍵過渡階段減少對個人或團隊的依賴。

採用嚴格的混合方法研究途徑，結合主要相關人員訪談、文件檢驗和情境壓力測試，以獲得有彈性的策略見解

本分析所依據的研究將結構化的一手資料與行業相關人員、嚴謹的二手資料整合以及基於場景的供應鏈壓力測試相結合，以確保獲得切實可行的見解。主要工作包括與申辦方和受託製造製造商的研發科學、品質保證、法規事務、採購和營運部門的高階領導進行訪談。這些對話重點在於能力差距、近期投資、技術轉移經驗以及對政策和供應中斷的實際應對措施。

二次研究考察了監管指南文件、技術白皮書和公開的企業資料，以檢驗觀察到的趨勢並繪製能力足跡圖。在可能的情況下，我們還進行了生產基地描述、設施審核和交叉引用的備案歷史記錄，以支援關於服務交付和模式覆蓋範圍的斷言。情境分析模擬了供應中斷、關稅引發的成本衝擊以及生產能力損失事件，以評估各種採購配置和合約結構的彈性。

分析方法包括跨細分維度的能力映射、定性比較分析（用於識別高績效供應商之間的差異化實踐）以及在各種顛覆情境下對採購和承包槓桿進行敏感性測試。研究過程強調三角測量，力求在訪談資料、文獻證據和情境結果之間達成一致，以得出確鑿的結論，同時承認政策軌跡和資本部署時間表存在不確定性。

簡要總結產能整合、供應多樣化和現代承包如何成為合約製造競爭韌性的支柱。

受技術、監管、商業性和地緣政治因素的影響，製藥製造合約和營運的格局正在迅速演變。投資於平台多功能性、高級分析和數位化控制的契約製造製造商最有能力滿足生技藥品和小分子產品贊助商的複雜需求。策略性採購選擇，包括近岸外包和供應商多元化，已成為管理成本和連續性風險的重要槓桿，尤其是在不斷變化的貿易政策可能對投入經濟產生重大影響的環境下。

能夠整合開發、分析和商業製造功能，最大限度地減少技術轉移摩擦並加快進度的組織將獲得長期競爭優勢。同時，強而有力的供應商來源管治和透明分配投入成本風險的合約機制，對於保護淨利率和維持可靠供應至關重要。未來將青睞以合作為夥伴關係的模式，這些模式能夠協調獎勵，並共用產品品質和及時市場進入的課責。果斷採取行動，加強靈活產能、制定應急計畫並現代化合約方式的決策者，將能夠將當前的混亂轉化為持久的策略效益。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 對提供全整合生物製藥開發和製造服務的 CDMO 的需求不斷增加
  • 擴大採用連續製造技術來提高製程效率和質量
  • 採用永續綠色化學實踐的小分子 API契約製造越來越受到青睞
  • 個人化醫療的發展需要針對細胞和基因治療的靈活契約製造解決方案
  • 製藥公司與 CDMO 建立策略夥伴關係關係，推動端到端流程數位化和自動化
  • 在整個外包製造工作流程中實施先進的品質分析和即時過程監控
  • 主要市場的監管協調正在推動對擁有全面全球合規專業知識的 CDMO 的需求
  • 疫苗和腫瘤供應鏈優先事項推動無菌注射契約製造需求激增
  • 增加對一次性反應器技術的投資，以加速生物製藥契約製造規模化進程
  • 將人工智慧驅動的流程最佳化平台整合到製藥契約製造營運中，以提高產量比率

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

8. 醫藥契約製造市場（依服務類型）

  • 分析服務
    • 生物分析服務
    • 方法開發
    • 穩定性研究
  • 開發服務
    • 配方開發
    • 製程開發
  • 灌裝服務
    • 注射器填充
    • 單位劑量灌裝
    • 管瓶灌裝
  • 製造服務
    • 液體口服製劑
    • 口服固態製劑
    • 無菌注射劑
    • 外用藥物
  • 包裝和標籤
    • 初級包裝
    • 二次包裝

9. 按分子類型分類的醫藥契約製造市場

  • 生技藥品
  • 小分子

第 10 章 藥品契約製造市場（以劑型）

  • 液體劑量
    • 口服溶液
    • 暫停
  • 固態劑型
    • 膠囊
    • 藥片
  • 無菌注射劑
  • 局部劑量
    • 乳膏和軟膏
    • 凝膠

第 11 章：按客戶類型分類的醫藥契約製造市場

  • 生物相似藥製造商
  • 學名藥製造商
  • 創新製造商

第 12 章：按治療領域分類的醫藥契約製造市場

  • 心血管系統
  • 中樞神經系統
  • 感染疾病
  • 腫瘤學

第 13 章：按合約類型分類的醫藥契約製造市場

  • 專用型
  • 非專用

第14章 醫藥契約製造市場（依製造規模）

  • 實驗室檢查
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的

第 15 章：按製程類型分類的醫藥契約製造市場

  • 批次
  • 連續的

第 16 章：按地區分類的醫藥契約製造市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 醫藥契約製造市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 18 章：各國醫藥契約製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭態勢

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Lonza Group AG
    • Catalent, Inc.
    • Thermo Fisher Scientific Inc.
    • Samsung Biologics Co., Ltd.
    • Wuxi AppTec Co., Ltd.
    • Fujifilm Diosynth BIoTechnologies US, LLC
    • Recipharm AB
    • Siegfried Holding AG
    • Cambrex Corporation
    • PCI Pharma Services, Inc.
Product Code: MRR-030EE48515DD

The Pharmaceutical Contract Manufacturing Market is projected to grow by USD 241.16 billion at a CAGR of 8.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 123.64 billion
Estimated Year [2025] USD 134.44 billion
Forecast Year [2032] USD 241.16 billion
CAGR (%) 8.70%

An authoritative orientation to how contract manufacturing has transformed from a cost-driven option into a strategic capability for pharmaceutical innovation and supply resilience

The pharmaceutical contract manufacturing arena occupies a pivotal role in the global medicines supply chain, enabling innovators, generics players, and biosimilar developers to translate laboratory breakthroughs into scalable, regulated commercial products. Outsourcing of production, formulation development, analytical testing, and packaging has evolved from a cost containment tactic into a strategic capability that supports speed to market, portfolio flexibility, and risk diversification. Stakeholders across the value chain now view contract manufacturing organizations as partners that co-own technical risk, compliance pathways, and lifecycle management responsibilities rather than as mere capacity vendors.

Today's landscape is shaped by converging pressures: complex biologic modalities that require specialized sterile and cold-chain capabilities; regulatory expectations for robust quality systems and supply traceability; and commercial demands for faster clinical-to-commercial transitions. These dynamics have elevated the importance of integrated service models that combine development expertise, analytical depth, and commercial-scale manufacturing. Consequently, forward-looking sponsors prioritize long-term technical relationships, modular manufacturing footprints, and transparency in supply risk, positioning contract manufacturers as central nodes in pharmaceutical innovation and distribution strategies.

How technological advances, regulatory tightening, and geopolitical pressures are converging to redefine contract manufacturing capabilities and strategic sourcing models

Recent years have seen a rapid reshaping of how contract manufacturing supports drug development and commercialization, driven by technological advances, regulatory complexity, and evolving stakeholder expectations. The rise of advanced biologics and cell and gene therapies has pushed CDMOs to invest in sterile injectables and cold chain platforms, while continuous manufacturing and process intensification have begun to reframe production economics and facility design. These shifts are not isolated; they simultaneously reshape commercial sourcing models, capital planning, and talent requirements across the industry.

Regulators globally are reinforcing expectations for quality-by-design, process robustness, and supply chain transparency, prompting manufacturers and their partners to embed analytics and digital thread capabilities across development and production lifecycles. Meanwhile, the industry's geographic footprint is adapting to geopolitical and trade developments, with localized capacity, dual-sourcing strategies, and nearshoring gaining prominence as mechanisms to mitigate disruption. Taken together, these transformative currents favor contract manufacturers that can demonstrate platform standardization, cross-modal expertise, and an agile approach to integrating regulatory, technical, and commercial needs into cohesive delivery models.

Understanding the broad operational and commercial consequences of new United States tariff measures in 2025 and how they reshape sourcing, investment, and contractual strategies

The tariff policy adjustments implemented by the United States in 2025 have introduced a new layer of complexity into the sourcing calculus for pharmaceutical ingredients, packaging components, and capital equipment, compelling both contract manufacturers and their sponsor customers to revisit cost structures and supply risk models. Increased duties on certain imported materials and equipment have translated into higher landed costs for components essential to sterile filling, specialized packaging substrates, and sophisticated analytical instrumentation. This dynamic has consequences across the development-to-commercial continuum: clinical supply budgets are pressured, capital expenditure plans for new facilities or equipment require recalibration, and pricing discussions between sponsors and CDMOs must account for elevated input cost volatility.

Beyond the direct cost impact, the tariffs have accelerated strategic behaviors that alter long-term industry structure. Some sponsors have prioritized re-shoring or near-shoring initiatives to reduce exposure to trade friction, which in turn increases demand for domestic capacity in steriles, biologics fill-finish, and specialized packaging. Contract manufacturers with flexible production models and multi-jurisdictional footprints have found increased interest from customers seeking rapid contingency options and shorter logistics chains. At the same time, suppliers of raw materials located in tariff-affected geographies are exploring re-certification pathways, dual-sourcing arrangements, and tariff-engineering solutions to preserve competitiveness.

The cumulative effect of these policy changes extends to supplier negotiations and commercial contracting. Cost escalation clauses, pass-through mechanisms, and inventory financing arrangements have become focal points of new contracts. Sponsors and CDMOs are seeking greater transparency on bill-of-materials composition and origin, and are more frequently agreeing to longer-term procurement commitments to secure stable pricing. Moreover, regulatory authorities and industry groups have engaged in dialogue about maintaining supply continuity for essential medicines, which has encouraged stakeholders to develop contingency playbooks that combine strategic stockpiles, multiple manufacturing sites, and prioritized allocation frameworks for critical components.

In sum, tariffs enacted in 2025 function less as a temporary price shock and more as a catalyst for structural change: they have shifted sourcing strategies toward resilience and localization, elevated the value of manufacturing flexibility, and forced sharper alignment between commercial terms and supply chain realities. Organizations that proactively integrate tariff risk into scenario planning, capital investment decisions, and supplier governance will be better positioned to sustain supply continuity and preserve margins while maintaining compliance and product quality.

Strategic segmentation analysis revealing capability demands across services, molecules, dosage forms, customer archetypes, therapeutic focuses, contract models, production scales, and process choices

A nuanced segmentation view reveals where capability gaps and strategic priorities converge across service modalities, molecule classes, dosage formats, customer archetypes, therapeutic focus, contract models, production phases, and process design choices. Service-type specialization spans analytical services that cover bioanalytical work, method development, and stability studies; development services that encompass formulation and process development; filling services that include syringe, unit dose, and vial filling; manufacturing services oriented to liquid orals, solid oral dosage, sterile injectables, and topical formulations; and packaging and labeling services that address primary and secondary packaging needs. Each service strand demands distinct capital intensity, regulatory pathways, and technical competencies, and firms that can offer integrated handoffs between development, analytical characterization, and commercial manufacturing create tangible time-to-market advantages for sponsors.

Molecule type drives technical complexity and facility requirements. Biologics require specialized upstream and downstream processing, cold chain considerations, and sterile handling regimes, while small molecules often align with established solid oral or liquid oral manufacturing platforms. Dosage form segmentation further refines capability needs: liquid dosage formats including oral solutions and suspensions necessitate excipient sourcing and stability expertise; solid dosage capsules and tablets demand robust formulation development and compression/fill capabilities; sterile injectables impose stringent aseptic practices and validated fill-finish suites; and topical dosage forms such as creams, ointments, and gels require formulation rheology control and container compatibility testing.

Customer type and therapeutic area shape commercial engagement models. Biosimilar manufacturers often seek high-volume commercial capacity and regulatory comparability expertise, generic manufacturers prioritize rapid scale-up and cost-efficient tooling, and innovator manufacturers demand integrated development pathways and controlled tech transfer. Therapeutic focus areas, such as cardiovascular, central nervous system, infectious diseases, and oncology, impose differing requirements for clinical supply chain timing, packaging and labeling complexity, and regulatory interaction intensity. Contract type and production scale introduce governance and utilization dynamics: dedicated contracts provide capacity assurance and long-term alignment, whereas non-dedicated models offer flexibility but require more complex scheduling. Clinical-scale production, with phase-specific needs across Phase I, II, and III, requires nimble tech transfer and batch documentation practices that differ materially from commercial-scale operations. Finally, process type-batch versus continuous-affects capital deployment, process monitoring complexity, and implications for scale-up. Continuous processes can enable higher throughput and more consistent product quality for certain modalities but require a higher level of process control and real-time analytical capabilities. Mapping capabilities against these segmentation axes allows stakeholders to identify where to consolidate partnerships, where to invest in capability development, and where to prioritize risk mitigation to support therapeutic and commercial objectives.

How regional capacity, regulatory complexity, and strategic incentives in the Americas, Europe Middle East & Africa, and Asia-Pacific shape manufacturing footprints and sourcing decisions

Regional dynamics are shaping where capacity is built, how supply risk is managed, and which regulatory touchpoints dominate commercial considerations. In the Americas, demand for sterile injectables, advanced biologics fill-finish, and secure supply chains has driven investments in domestic capacity and specialization. This region's combination of regulatory clarity, large commercial markets, and proximity to major sponsor headquarters makes it attractive for nearshoring initiatives and for sponsors seeking shorter lead times and more responsive technical collaboration.

Europe, Middle East & Africa represents a diverse regulatory and capability landscape where established CDMOs co-exist with niche innovators. European manufacturing networks often emphasize harmonized regulatory pathways and advanced process technologies, while countries across the broader region offer differentiated cost structures and emerging specialized capabilities. Cross-border regulatory alignment within this region influences where multicountry batch release strategies and centralized quality oversight are implemented, which affects the design of multi-site manufacturing networks.

Asia-Pacific continues to be a critical capacity hub, offering broad manufacturing bases for small molecules, generics, and an expanding footprint for biologics and sterile manufacturing. The region's competitive cost profile, deep supplier networks for excipients and packaging materials, and growing technical talent pool make it a central node for both clinical and commercial production. Simultaneously, increasing regulatory sophistication in several Asia-Pacific markets and rising domestic demand are pushing local providers to upgrade quality systems and to pursue international certifications, which in turn broadens the set of viable sourcing options for global sponsors.

Across these geographies, supply chain resilience, regulatory convergence efforts, and strategic incentives for local manufacturing are the common themes influencing investment decisions. Sponsors and contract manufacturers must evaluate trade-offs between cost, lead time, regulatory complexity, and risk exposure when configuring global footprints; the optimal approach increasingly blends regional centers of excellence with redundant capacity and rapid-response capabilities.

Insights into how capability consolidation, platform specialization, and deep client partnerships are reshaping competitive positioning among contract manufacturing providers

Competitive dynamics among leading contract manufacturers and service providers are characterized by capability consolidation, platform differentiation, and deeper client partnerships that extend beyond transactional engagements. Many firms are moving up the value chain by offering integrated development-to-commercial solutions that reduce tech transfer friction and accelerate commercialization timelines. This trend is visible in the expansion of analytical platforms that support complex biologics, investments in sterile fill-finish capacity, and the adoption of digital quality and manufacturing execution systems to enable more predictable outcomes.

Strategic partnerships, mergers, and targeted greenfield investments are being used to expand modality coverage and geographic presence, while mid-sized specialized players often succeed by focusing on niche capabilities such as high-potency handling, complex packaging, or rapid-turn clinical supply. For sponsors, the choice of partner reflects a balance between scale, technical specialization, and the depth of regulatory experience. Increasingly, procurement teams value partners who can demonstrate demonstrable process ruggedness, a track record of successful tech transfers, and transparent governance over multi-supplier supply chains.

Talent and leadership continuity are notable differentiators. Organizations that retain cross-functional teams covering development sciences, regulatory affairs, quality assurance, and operational excellence are better equipped to navigate complex projects and minimize time-to-release delays. Additionally, firms that provide clear roadmaps for capacity expansion and contingency management tend to attract longer-term commitments from customers seeking to de-risk their product launches and lifecycle supply.

Practical strategic actions for manufacturers and sponsors to enhance flexibility, mitigate supply risks, and align commercial frameworks with evolving production realities

Industry leaders should prioritize a series of tactical and strategic actions to convert current market dynamics into sustainable advantage. First, invest selectively in modular and flexible manufacturing platforms that can accommodate multiple dosage forms and molecule classes, thereby enabling rapid redeployment across projects and reducing time lost to retooling. Embedding robust analytical technologies and digital process controls will support quality-by-design approaches and facilitate smoother scale-up pathways from clinical to commercial production.

Second, re-evaluate supplier and sourcing strategies to mitigate tariff exposure and logistical risk. This includes diversifying input suppliers, negotiating clearer pass-through clauses, and developing nearshore alternatives where feasible. Transparent supply-of-origin documentation and a proactive approach to supplier qualification will improve negotiating leverage and reduce downstream surprises.

Third, strengthen integrated development pathways by co-locating or tightly coordinating formulation, analytical, and process development teams with manufacturing operations. This alignment shortens feedback loops, accelerates tech transfer, and reduces regulatory friction at the point of scale-up. Complementary to this, establish formal contingency playbooks for critical material shortages and regulatory delays, including prioritized allocation criteria and pre-agreed surge capacity arrangements with trusted partners.

Fourth, adopt outcome-oriented commercial models with customers, such as milestone-linked pricing and risk-sharing arrangements, to better align incentives and accommodate input cost volatility. Develop contract frameworks that include clear escalation mechanisms for input cost shocks while preserving collaborative governance for change management. Finally, prioritize talent development programs that cross-train scientists, quality professionals, and operations staff to build institutional resilience and reduce dependency on single individuals or teams during critical transfer phases.

A rigorous mixed-methods research approach combining primary stakeholder interviews, documentary validation, and scenario stress testing to produce resilient strategic insights

The research underpinning this analysis combined structured primary engagement with industry stakeholders, rigorous secondary source synthesis, and scenario-based supply chain stress testing to ensure actionable and defensible insights. Primary engagement included interviews with senior leaders across development sciences, quality assurance, regulatory affairs, procurement, and operations from a spectrum of sponsor and contract manufacturing organizations. These conversations focused on capability gaps, recent investments, tech transfer experiences, and practical responses to policy or supply disruptions.

Secondary research reviewed regulatory guidance documents, technical white papers, and publicly available corporate disclosures to validate observed trends and to map capability footprints. Where possible, cross-referencing of production platform descriptions, facility audits, and filing histories was used to corroborate claims about service offerings and modality coverage. Scenario-based analysis simulated supply interruptions, tariff-induced cost shocks, and capacity loss events to evaluate the resilience of different sourcing configurations and contract structures.

Analytical methods included capability mapping across the segmentation dimensions, qualitative comparative analysis to identify differentiating practices among high-performing providers, and sensitivity testing of procurement and contracting levers under varying disruption scenarios. The research process emphasized triangulation, seeking concurrence across interview data, documentary evidence, and scenario outcomes to build robust conclusions while acknowledging uncertainty in policy trajectories and capital deployment timelines.

A concise synthesis of how capability integration, supply diversification, and modern contracting form the pillars of competitive resilience in contract manufacturing

The contractual and operational contours of pharmaceutical manufacturing are evolving rapidly under the influence of technological, regulatory, commercial, and geopolitical forces. Contract manufacturers that invest in platform versatility, advanced analytics, and digital controls will be best positioned to serve the complex needs of biologic and small-molecule sponsors alike. Strategic sourcing choices, inclusive of nearshoring and supplier diversification, have become critical levers to manage both cost and continuity risk, particularly in an environment where trade policy shifts can materially affect input economics.

Longer-term competitive advantage will accrue to organizations that can integrate development, analytical, and commercial manufacturing functions to minimize tech transfer friction and compress timelines. At the same time, strong governance over supplier origin and contractual mechanisms that transparently allocate input cost risk will be essential for preserving margins and maintaining reliable supply. The future will favor collaborative, partnership-oriented models that align incentives and create shared accountability for product quality and timely market access. Decision-makers who act decisively to fortify flexible capacity, codify contingency plans, and modernize contracting approaches will convert current disruption into durable strategic benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing demand for CDMOs providing fully integrated biologics development and manufacturing services
  • 5.2. Rising adoption of continuous manufacturing technologies to enhance process efficiency and quality
  • 5.3. Growing preference for small molecule API contract manufacturing adopting sustainable green chemistry practices
  • 5.4. Expansion of personalized medicine requiring flexible contract manufacturing solutions for cell and gene therapies
  • 5.5. Strategic partnerships between pharmaceutical firms and CDMOs to drive end-to-end process digitalization and automation
  • 5.6. Implementation of advanced quality analytics and real-time process monitoring across outsourced production workflows
  • 5.7. Regulatory harmonization across major markets increasing demand for CDMOs with comprehensive global compliance expertise
  • 5.8. Surge in requests for sterile injectable contract manufacturing driven by vaccine and oncology supply chain priorities
  • 5.9. Increased investment in single-use bioreactor technologies to accelerate biologics contract manufacturing scale-up timelines
  • 5.10. Integration of AI-driven process optimization platforms into pharmaceutical contract manufacturing operations for yield improvement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing Market, by Service Type

  • 8.1. Analytical Services
    • 8.1.1. Bioanalytical Services
    • 8.1.2. Method Development
    • 8.1.3. Stability Studies
  • 8.2. Development Services
    • 8.2.1. Formulation Development
    • 8.2.2. Process Development
  • 8.3. Filling Services
    • 8.3.1. Syringe Filling
    • 8.3.2. Unit Dose Filling
    • 8.3.3. Vial Filling
  • 8.4. Manufacturing Services
    • 8.4.1. Liquid Orals
    • 8.4.2. Solid Oral Dosage
    • 8.4.3. Sterile Injectables
    • 8.4.4. Topical Formulations
  • 8.5. Packaging & Labeling
    • 8.5.1. Primary Packaging
    • 8.5.2. Secondary Packaging

9. Pharmaceutical Contract Manufacturing Market, by Molecule Type

  • 9.1. Biologics
  • 9.2. Small Molecule

10. Pharmaceutical Contract Manufacturing Market, by Dosage Form

  • 10.1. Liquid Dosage
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Solid Dosage
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Sterile Injectables
  • 10.4. Topical Dosage
    • 10.4.1. Creams & Ointments
    • 10.4.2. Gels

11. Pharmaceutical Contract Manufacturing Market, by Customer Type

  • 11.1. Biosimilar Manufacturers
  • 11.2. Generic Manufacturers
  • 11.3. Innovator Manufacturers

12. Pharmaceutical Contract Manufacturing Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. CNS
  • 12.3. Infectious Diseases
  • 12.4. Oncology

13. Pharmaceutical Contract Manufacturing Market, by Contract Type

  • 13.1. Dedicated
  • 13.2. Non Dedicated

14. Pharmaceutical Contract Manufacturing Market, by Production Scale

  • 14.1. Clinical Trial
    • 14.1.1. Phase I
    • 14.1.2. Phase II
    • 14.1.3. Phase III
  • 14.2. Commercial

15. Pharmaceutical Contract Manufacturing Market, by Process Type

  • 15.1. Batch
  • 15.2. Continuous

16. Pharmaceutical Contract Manufacturing Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Pharmaceutical Contract Manufacturing Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Pharmaceutical Contract Manufacturing Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Lonza Group AG
    • 19.3.2. Catalent, Inc.
    • 19.3.3. Thermo Fisher Scientific Inc.
    • 19.3.4. Samsung Biologics Co., Ltd.
    • 19.3.5. Wuxi AppTec Co., Ltd.
    • 19.3.6. Fujifilm Diosynth Biotechnologies US, LLC
    • 19.3.7. Recipharm AB
    • 19.3.8. Siegfried Holding AG
    • 19.3.9. Cambrex Corporation
    • 19.3.10. PCI Pharma Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2025